HEALTH

Prostate Test Finding Boosts Company’s Stock: The stock of Biomerica Inc., a Newport Beach-based maker of medical diagnostic test kits, soared fourfold in a trading frenzy over news that it is poised to produce a quick and easy method to detect one of the early warning signs of prostate cancer. Biomerica stock rocketed $7.375 a share to close at $9.75 on the Nasdaq market system. For the last year, the stock had been trading in a range of $1 to $3 a share. The sharp rise is certain to set off alarms at the National Assn. of Securities Dealers, which regulates the Nasdaq market, and trigger a routine inquiry.